# Aier Eye Hospital Group

> Aier Eye Hospital Group is a VC fund backing Medical Device and Medical. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Changsha, China
- Total investments: 10
- Last investment: Sep 2025
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/aier-eye-hospital-group-co-ltd-
- X (Twitter): https://twitter.com/aiereyehospital
- Website: http://www.aierchina.com/
- Facebook: https://www.facebook.com/Aiereyehospital/

Aier Eye Hospital Group is a VC fund in Changsha focused on Medical Device and Medical. Aier Eye Hospital Group offers surgery for myopia; prevention and treatment for myopia; treatment for cataract, glaucoma, pediatric ophthalmology, fundus disease, lacrimal disease, and cornea and ocular surface; and eye shaping beauty services.

## Contacts

5 contacts available for Aier Eye Hospital Group. Shizune tracks 3 team members at Aier Eye Hospital Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aier-eye-hospital-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 3 | 30% |
| Medical | 2 | 20% |
| Software | 2 | 20% |
| Health Care | 2 | 20% |
| Biotechnology | 2 | 20% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Post-IPO Equity | 2 | 20% |
| Seed | 1 | 10% |
| Series C | 1 | 10% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 7 | 70% |
| Hong Kong | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bang Chen | Founder | 0 | https://shizune.co/investors/profile/bang-chen-f286 |
| Li Li | Founder | 0 | https://shizune.co/investors/profile/li-li-1855 |
| Michael Lau | CEO | 0 | https://shizune.co/investors/profile/michael-lau-0ec8 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kangdesai Medical Technology | Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrenceand metastasis. |  | Series A | Sep 22, 2025 |  |
| Sieran Medical | Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology. | $14.1M | Seed | Sep 05, 2024 |  |
| Svision | Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. | $43.1M | Series C | Mar 09, 2023 |  |
| SIYO Bio-Tech | SIYO Bio-Tech is a bioengineering company that focuses on research & innovation of microbial enzyme preparation technology. | $31.7M | Series B | Feb 23, 2022 |  |
| Svision | Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. |  | Venture - Series Unknown | Dec 31, 2021 |  |
| Zhaoke Ophthalmology Pharmaceutical | Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform. | $145M | Series B | Oct 12, 2020 |  |
| The Kocla Smart Classes | The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. | $5.1M | Post-IPO Equity | Mar 20, 2017 |  |
| CloudClip | CloudClip is a technology company that focuses on researching the myopia problem in young people and providing systematic solutions. They provide each user with customized eye-care training programs and help children develop a healthy eye-use habit. | $1.4M | Series A | Dec 31, 2016 |  |
| Qihoo 360 Technology | Qihoo 360 Technology Co Ltd (Qihoo 360), formerly Qihoo Technology Company Limited, is engaged in the operations of Internet services and sales of third party anti-virus software in the People's Republic of China. It provides Internet and mobile security products in China. In January 2011, the Company had 328 million monthly active Internetsecurity product users, representing a user penetration rate of 83.9% in China. Its Internet and mobile security products include 360 Safe Guard and 360 Anti-virus, the Internet security products in China, with 301 million and 248 million monthly active users in January 2011, and 360 Mobile Safe, the mobile security product in China. The Company generates revenues primarily through offering the services, such as online advertising and Internet value-added services. Online advertising offers advertising services by providing marketing opportunities on its Websites and secure platform products to its advertising customers. | $30M | Post-IPO Equity | Sep 28, 2016 |  |
| The Kocla Smart Classes | The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. | $7.1M | Series D | Jul 20, 2015 |  |

10 of 10 investments shown.

## Co-investors
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 2 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 1 deal together
- [Aibo Qingshi Venture Capital Fund](https://shizune.co/investors/profile/aibo-qingshi-venture-capital-fund) — VC Fund, 1 deal together
- [Apricot Capital](https://shizune.co/investors/profile/apricot-capital-ceb8) — VC Fund, 1 deal together
- [CD Capital](https://shizune.co/investors/profile/cd-capital) — VC Fund, 1 deal together
- [China Life Private Equity Investment](https://shizune.co/investors/profile/china-life-private-equity-investment) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Aier Eye Hospital Group invest in?

Aier Eye Hospital Group invests primarily in Medical Device, Medical and Software startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aier Eye Hospital Group?

Public channels for Aier Eye Hospital Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aier Eye Hospital Group?

The team at Aier Eye Hospital Group includes Bang Chen (Founder), Li Li (Founder) and Michael Lau (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co